CIK 0000943819 · Large accelerated filer
RESMED INC
Sign in to watch- Tickers
- RMD RSMDF
- Exchange
- NYSE, OTC
- Industry
- Surgical & Medical Instruments & Apparatus
- FY end
- Jun 30
- Incorporated
- DE
- Entity type
- operating
- EIN
- 980152841
- Phone
- 8587462400
- Business address
- 9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA, 92123
Securities
- RMD ResMed Inc. Common Stock NYSE
- RSMDF Common stock OTC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $3,744,605
- in 5 filings, $3.7M under 10b5-1 plans
Net −$3,744,605. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-10-11 | Ghoshal Kaushik Chief Commercial Officer, SaaS | Option exercise 10b5-1 | +4,260 | $101.64 | $433K | 26,048 |
| 2024-10-11 | Ghoshal Kaushik Chief Commercial Officer, SaaS | Sale 10b5-1 | −4,260 | $238.48 | $1.0M | 21,788 |
| 2024-10-11 | Ghoshal Kaushik Chief Commercial Officer, SaaS | Option exercise · ResMed Common Stock Options 10b5-1 | −4,260 | 0 | ||
| 2024-10-08 | Sandercock Brett Chief Financial Officer | Sale 10b5-1 | −1,000 | $233.47 | $233K | 95,812 |
| 2024-10-07 | Farrell Michael J. Chief Executive Officer | Option exercise 10b5-1 | +14,683 | $84.98 | $1.2M | 478,852 |
| 2024-10-07 | Farrell Michael J. Chief Executive Officer | Sale 10b5-1 | −14,683 | $231.91 | $3.4M | 464,169 |
| 2024-10-07 | Farrell Michael J. Chief Executive Officer | Option exercise · ResMed Common Stock Options 10b5-1 | −14,683 | 14,683 | ||
| 2024-10-02 | FARRELL PETER C Director | Sale 10b5-1 | −2,000 | $237.20 | $474K | 85,204 |
| 2024-09-12 | Ghoshal Kaushik Chief Commercial Officer, SaaS | Option exercise 10b5-1 | +5,000 | $101.64 | $508K | 26,788 |
| 2024-09-12 | Ghoshal Kaushik Chief Commercial Officer, SaaS | Sale 10b5-1 | −5,000 | $252.56 | $1.3M | 21,788 |
| 2024-09-12 | Ghoshal Kaushik Chief Commercial Officer, SaaS | Option exercise · ResMed Common Stock Options 10b5-1 | −5,000 | 4,260 | ||
| 2024-09-09 | Sandercock Brett Chief Financial Officer | Sale 10b5-1 | −1,000 | $246.42 | $246K | 96,812 |
| 2024-09-09 | Farrell Michael J. Chief Executive Officer | Option exercise 10b5-1 | +14,683 | $84.98 | $1.2M | 478,852 |
| 2024-09-09 | Farrell Michael J. Chief Executive Officer | Sale 10b5-1 | −14,683 | $248.38 | $3.6M | 464,169 |
| 2024-09-09 | Farrell Michael J. Chief Executive Officer | Option exercise · ResMed Common Stock Options 10b5-1 | −14,683 | 29,366 | ||
| 2024-09-04 | FARRELL PETER C Director | Sale 10b5-1 | −2,000 | $239.90 | $480K | 87,204 |
| 2024-09-03 | DelOrefice Christopher Director | Grant or award | +267 | 267 | ||
| 2024-08-20 | Rider Michael J Global General Counsel | Sale 10b5-1 | −882 | $231.00 | $204K | 10,512 |
| 2024-08-15 | Sandercock Brett Chief Financial Officer | Grant or award | +7,915 | 96,971 | ||
| 2024-08-15 | Sandercock Brett Chief Financial Officer | Grant or award | +841 | 97,812 |
Page 13 of 19 · 361 trades